MedPageToday -- SAN ANTONIO -- Preliminary results of a neoadjuvant breast cancer therapy trial for HER2-positive tumors shows that a four-drug combination has a high pathological complete response rate, researchers said here.
MedPageToday -- SAN ANTONIO -- Preliminary results of a neoadjuvant breast cancer therapy trial for HER2-positive tumors shows that a four-drug combination has a high pathological complete response rate, researchers said here.
